• Alpha-Thalassemia
  • Semen Analysis
  • Cytochrome P450 21A2 (CYP21A2) Genotyping
  • Diphtheria Toxoid Antibody, IgG
  • Human Papillomavirus (HPV) Typing, DNA In Situ Hybridization
  • Products of Conception (POC) Aneuploidy Detection, FISH, Tissue
  • Neuron Specific Enolase (NSE), CSF
  • Zika Virus, Molecular
  • Circulating Tumor Cells (CTC), Prostate Cancer
  • Plasminogen Activator Inhibitor Antigen, Plasma
  • LDS
  • Sign up
  • Log in
  • LDS
  • /Medical Tests
  • /Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References

Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management
Medical Test

Methodology
Access to Guardant360 TissueNext™, Lung and Breast Cancer Therapy Management is restricted.
Loading...